Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

The company reported sales of $2.65 billion, up 7% year over year on a reported basis, 8% on constant currency, beating the consensus of $2.32 billion.

Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Sales of the multiple sclerosis drug Tysabri were down to $454.6 million from $462.2 million.

Also Read: Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis’ Zolgensma

Rare disease revenue increased 2% year over year (up 3% on constant currency) to $543 million. Spinraza’s revenue decreased to $392.7 million from $429.1 million a year ago.

Revenues from Skyclarys, acquired via the Reata acquisition, reached $130.3 million during the quarter, up from $100 ...